Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?

被引:139
作者
Melief, CJM [1 ]
机构
[1] Leiden Univ, Ctr Med, Dept Immunohaematol & Blood Transfus, NL-2300 RA Leiden, Netherlands
关键词
cross-priming; cross-tolerance; CTL; DC;
D O I
10.1002/eji.200324341
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Cross-priming is the process whereby professional APC, mainly dendritic cells (DC), prime T cells by presenting antigens processed from proteins of other cells such as tumor cells or virus-infected cells. It has been argued that the importance of cross-priming of CD8(+) CTL responses has been overemphasized, despite strong evidence that these mechanisms operate when infectious organisms, tumors or self antigens cannot efficiently access the biosynthetic MHC class I processing pathway of DC. Since DC are ideally equipped to capture exogenous antigen and also, particularly in the mature state, express costimulatory molecules, it is difficult to distinguish whether effects are due to cross-presentation, costimulation, or both. Whether cross-priming or cross-tolerance occurs depends on the maturation state of the DC, as well as the levels of MHC class I-bound peptides they present. Cross-presentation of tumor-derived antigens has been demonstrated but, importantly, requires adequate APC activation to prime CTL responses. Similarly, cross-presentation of antigens from infectious organisms appears to be common, and frequently leads to cross-priming. Interactions between cross-presenting DC, CD4(+) cells and CD8(+) T cells in the establishment of immunological memory are still not well defined. Experiments utilizing DC depletion are needed to further examine the role of processes such as cross-priming and costimulation in the immune response.
引用
收藏
页码:2645 / 2654
页数:10
相关论文
共 84 条
[1]
αvβ5 integrin recruits the Crkll-Dock180-Rac1 complex for phagocytosis of apoptotic cells [J].
Albert, ML ;
Kim, JI ;
Birge, RB .
NATURE CELL BIOLOGY, 2000, 2 (12) :899-905
[2]
Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].
Albert, ML ;
Sauter, B ;
Bhardwaj, N .
NATURE, 1998, 392 (6671) :86-89
[3]
Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes [J].
Albert, ML ;
Pearce, SFA ;
Francisco, LM ;
Sauter, B ;
Roy, P ;
Silverstein, RL ;
Bhardwaj, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (07) :1359-1368
[4]
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[5]
TLR4 mutations are associated with endotoxin hyporesponsiveness in humans [J].
Arbour, NC ;
Lorenz, E ;
Schutte, BC ;
Zabner, J ;
Kline, JN ;
Jones, M ;
Frees, K ;
Watt, JL ;
Schwartz, DA .
NATURE GENETICS, 2000, 25 (02) :187-+
[6]
Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[7]
Signaling through OX40 (CD134) breaks peripheral T-cell tolerance [J].
Bansal-Pakala, P ;
Jember, AGH ;
Croft, M .
NATURE MEDICINE, 2001, 7 (08) :907-912
[8]
The CD8α+ dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens [J].
Belz, GT ;
Behrens, GMN ;
Smith, CM ;
Miller, JFAP ;
Jones, C ;
Lejon, K ;
Fathman, CG ;
Mueller, SN ;
Shortman, K ;
Carbone, FR ;
Heath, WR .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (08) :1099-1104
[9]
Help for cytotoxic-T-cell responses is mediated by CD40 signalling [J].
Bennett, SRM ;
Carbone, FR ;
Karamalis, F ;
Flavell, RA ;
Miller, JFAP ;
Heath, WR .
NATURE, 1998, 393 (6684) :478-480
[10]
Human CD8+ T cell responses to EBV EBNA1:: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing [J].
Blake, N ;
Lee, S ;
Redchenko, I ;
Thomas, W ;
Steven, N ;
Leese, A ;
Steigerwald-Mullen, P ;
Kurilla, MG ;
Frappier, L ;
Rickinson, A .
IMMUNITY, 1997, 7 (06) :791-802